Specializing in CMC Development and Manufacturing of Biologics: Monoclonal Antibodies, Bispecific Antibodies, and Recombinant Proteins.
Since its establishment in 2016, Guangzhou Canton Biologics Co., Ltd. (hereinafter referred to as "Canton Biologics") has focused on the CMC development and manufacturing of biologics such as monoclonal antibodies, bispecific antibodies, and fusion proteins. The company provides global biopharmaceutical clients with one-stop services compliant with regulatory requirements of NMPA, FDA, and EMA. Service scope includes protein sequence optimization, cell line development, upstream and downstream process development, formulation development, analytical method development and validation, technology transfer, pilot-scale production (50/200L), commercial-scale production (2000L), and product release, consistently helping clients advance projects from the laboratory to patients.
Canton Biologics possesses internationally leading capabilities in engineered cell culture and development, upstream and downstream process development, analytical method development for biologics, formulation process development, quality testing method development, and pilot-scale and commercial-scale manufacturing. Since its inception, it has provided development and manufacturing services for biologics such as monoclonal antibodies, bispecific antibodies, fusion proteins, and recombinant proteins to numerous biopharmaceutical companies domestically and internationally. Its exceptional project management and rapid, efficient project delivery have earned widespread acclaim from clients.
300+
Scientists & Engineers
Canton Biologics' current laboratory and production facilities are distributed as follows：
Guangzhou Headquarters & R&D Center
3,600 sqm, providing services including protein sequence optimization, cell line development, upstream/downstream process development, analytical method development, bacterial/yeast/mammalian cell protein expression services, and process development and production services for viral vectors and cell therapy products.
Berlin R&D Center, Germany
800 sqm, providing services including cell line development, upstream/downstream process development, analytical method development, and clinical immunomonitoring services.
Foshan Kunlun GMP Manufacturing Site, China
12,000 sqm. The production line design and operations comply with Chinese, U.S., and European GMP standards, offering pilot-scale and commercial production services for projects such as cell culture and bio‑recombinant manufacturing.
Guangzhou Penglai GMP Manufacturing Site, China
14,000 sqm. The production line design and operations comply with Chinese, U.S., and European GMP standards, offering pilot-scale and commercial production services for projects involving microorganisms, viruses/vectors, and cell therapies.
As a National High‑Tech Enterprise, we are dedicated to providing domestic and international clients with end‑to‑end, one‑stop services for bio‑raw materials and biologic drugs, from discovery to commercial manufacturing.
Total Manufacturing Capacity
13000L
中文
